Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TumorSelect Paclitaxel (Cloaked Therapeutics Development)
- Development stage
- Preclinical
- Lead developer
- Cloaked Therapeutics Development
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Parenteral
01
Overview
TumorSelect Paclitaxel is a preclinical anticancer drug candidate developed by Cloaked Therapeutics that encapsulates paclitaxel in a proprietary pseudo-LDL lipid nanoparticle designed to exploit overexpressed low-density lipoprotein receptors on tumor cells. The TumorSelect platform is intended to mimic native LDL particles, promote tumor accumulation through nanoparticle delivery and receptor-mediated uptake, and then release paclitaxel intracellularly after endosomal processing, with the goal of improving the therapeutic index of paclitaxel by increasing tumor-selective delivery and reducing systemic toxicity. The program is being explored across multiple solid and hematologic malignancies, including breast cancer, colorectal cancer, gastric cancer, glioblastoma, leukemia, melanoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and prostate cancer.
- Brand names
- TumorSelect Paclitaxel
- Other names
- pseudo-LDL nanoparticle paclitaxel
02
Targets
LDLR (Low-density lipoprotein receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TumorSelect Paclitaxel (Cloaked Therapeutics Development).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TumorSelect Paclitaxel (Cloaked Therapeutics Development).